Advancing a class on top of statins
Investors & Media

Analyst Coverage

Canaccord GenuityJohn Newman,
Jefferies LLCMatthew J.
Laidlaw Capital MarketsFrancois
LifeSci Capital, LLCPatrick
Piper Jaffray & Co.Charles Duncan,
Raymond James and AssociatesLaura Chico,
Roth Capital PartnersYasmeen Rahimi,
Gemphire Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Gemphire Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Gemphire Therapeutics, Inc. or its management. Gemphire Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.